A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia.
The goals of optimal antimicrobial therapy are to treat infection effectively, to improve the clinical condition of the patient, and to prevent the emergence of resistant bacterial strains. For ideal drug usage the World Health Organization recommends administering the correct drug by the best route, in the right amount, at optimum intervals for the appropriate period, and after an accurate diagnosis. This article discusses the use of high-dose, short-course fluoroquinolone therapy as an effective option for patients with community-acquired pneumonia.
File
Thomas M
TM
Northeastern Ohio University College of Medicine, Rootstown, Ohio, USA.
D017714:Community-Acquired Infections / Q000188:drug therapy*; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015242:Ofloxacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D012449:Safety; D013997:Time Factors; D016896:Treatment Outcome
D024841:Fluoroquinolones; D015242:Ofloxacin